公开(公告)号：US20230302096A1

公开(公告)日：2023-09-28

申请号：US18047129

申请日：2022-10-17

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Philippe P. MONNIER ,  Nardos G. TASSEW

IPC: A61K38/44 ,  A61K31/137 ,  C07K16/28 ,  A61K31/724 ,  A61K31/365 ,  A61K31/7048 ,  A61K38/48 ,  C07K14/435 ,  C07K14/705 ,  G01N33/53 ,  A61K31/495 ,  A61K38/17 ,  G01N33/50

CPC classification number: A61K38/443 ,  A61K31/137 ,  C07K16/28 ,  C12Y101/03006 ,  A61K31/724 ,  A61K31/365 ,  A61K31/7048 ,  A61K38/482 ,  C07K14/435 ,  C07K14/705 ,  G01N33/53 ,  A61K31/495 ,  A61K38/177 ,  G01N33/5058 ,  A61K2039/505

Abstract: Disclosed herein is an agent that modulates a cis interaction between Repulsive Guidance Molecule A (RGMa) and Neogenin or lipid rafts. Modulation by the agent may include blocking the cis interaction between RGMa and Neogenin and/or disrupting lipid rafts. In turn, this promotes neuronal cell survival and axon growth and/or regeneration. Also disclosed herein is a method of treating a disease in a subject in need thereof. The method may include administering the agent to the subject. Further disclosed herein is a method of identifying an agent that modulates the cis interaction between RGMa and Neogenin.

公开(公告)号：US20160271230A1

公开(公告)日：2016-09-22

申请号：US14915492

申请日：2014-08-06

Applicant: UNIVERSITY HEALTH NETWORK (UHN): TECHNOLOGY DEVELOPMENT AND COMMERCIALIZATION

Inventor： Philippe P. MONNIER ,  Nardos G. TASSEW

IPC: A61K38/44 ,  C07K16/28 ,  G01N33/50 ,  A61K31/137 ,  A61K31/495 ,  A61K38/17 ,  A61K31/724

CPC classification number: A61K38/443 ,  A61K31/137 ,  A61K31/365 ,  A61K31/495 ,  A61K31/7048 ,  A61K31/724 ,  A61K38/177 ,  A61K38/482 ,  A61K2039/505 ,  C07K14/435 ,  C07K14/705 ,  C07K16/28 ,  C07K2317/30 ,  C07K2317/76 ,  C12Y101/03006 ,  G01N33/5058 ,  G01N33/53 ,  G01N2333/4703

Abstract: Disclosed herein is an agent that modulates a cis interaction between Repulsive Guidance Molecule A (RGMa) and Neogenin or lipid rafts. Modulation by the agent may include blocking the cis interaction between RGMa and Neogenin and/or disrupting lipid rafts. In turn, this promotes neuronal cell survival and axon growth and/or regeneration. Also disclosed herein is a method of treating a disease in a subject in need thereof. The method may include administering the agent to the subject. Further disclosed herein is a method of identifying an agent that modulates the cis interaction between RGMa and Neogenin.

Abstract translation: 本文公开了调节排斥导向分子A（RGMa）和新生物或脂质筏之间的顺式相互作用的试剂。 试剂的调节可能包括阻断RGMa和Neogenin之间的顺式相互作用和/或破坏脂筏。 反过来，这促进神经元细胞存活和轴突生长和/或再生。 本文还公开了治疗有需要的受试者的疾病的方法。 该方法可以包括向受试者施用该药剂。 本文进一步公开的是鉴定调节RGMa和Neogenin之间的顺式相互作用的试剂的方法。

公开(公告)号：US20190275118A1

公开(公告)日：2019-09-12

申请号：US16277529

申请日：2019-02-15

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Philippe P. MONNIER ,  Nardos G. TASSEW

IPC: A61K38/44 ,  A61K38/17 ,  A61K31/495 ,  G01N33/50 ,  A61K31/724 ,  A61K31/7048 ,  A61K31/365 ,  A61K31/137 ,  A61K38/48 ,  C07K16/28 ,  G01N33/53 ,  C07K14/435 ,  C07K14/705

Abstract: Disclosed herein is an agent that modulates a cis interaction between Repulsive Guidance Molecule A (RGMa) and Neogenin or lipid rafts. Modulation by the agent may include blocking the cis interaction between RGMa and Neogenin and/or disrupting lipid rafts. In turn, this promotes neuronal cell survival and axon growth and/or regeneration. Also disclosed herein is a method of treating a disease in a subject in need thereof. The method may include administering the agent to the subject. Further disclosed herein is a method of identifying an agent that modulates the cis interaction between RGMa and Neogenin.